Stock on Trader's Radar: Array Biopharma Inc (ARRY)

Modesto Morganelli
Dicembre 8, 2017

32 funds opened positions while 55 raised stakes. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.22). Northern holds 2.13 million shares or 0% of its portfolio. Canada Pension Plan Investment Board owns 136,000 shares for 0% of their portfolio. Similarly, investors look up the share price over 12 month periods. Leerink Swann downgraded Array BioPharma Inc. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Array BioPharma by 7.7% during the 1st quarter. (NASDAQ:ARRY). Ellington Group Ltd Company, a Connecticut-based fund reported 13,300 shares.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.

Several other large investors have also recently modified their holdings of ARRY. Cormorant Asset Mngmt Lc holds 1.25% or 900,000 shares. It also reduced its holding in Penumbra Inc by 102,964 shares in the quarter, leaving it with 931,444 shares, and cut its stake in Molina Healthcare Inc (NYSE:MOH). Teacher Retirement System of Texas lifted its position in Array BioPharma by 8.3% during the second quarter. The disposition, at a price of $10.9, resulted in Lunsen Van bringing total 19297 shares.

Strs Ohio has invested 0% in Array BioPharma Inc.

Celgene Corporation (NASDAQ: CELG) has grabbed attention from the analysts when it experienced a change of -0.05% in the last trading session to close at $102.56. About 725,408 shares traded.

Consequently Array Biopharma Inc (NASDAQ:ARRY)'s weekly and monthly volatility is 5.69%, 4.75% respectively. It has outperformed by 159.81% the S&P500.

Redmile Group Llc, which manages about $1.27B and $1.64 billion US Long portfolio, decreased its stake in Prothena Corp Plc (NASDAQ:PRTA) by 339,785 shares to 509,698 shares, valued at $27.59 million in 2017Q2, according to the filing.

More notable recent Array BioPharma Inc.

In other news, Director Kyle Lefkoff sold 38,865 shares of the firm's stock in a transaction on Friday, September 29th. The Return on Assets for Array BioPharma Inc. (NASDAQ:ARRY) were released by: and their article: "Array BioPharma Announces Redemption of All Remaining 3.00% Convertible Senior ..." published on December 05, 2017 as well as's news article titled: "ARRY INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of ..." with publication date: December 04, 2017. Out of the analyst recommendations 3 rate Array Biopharma Inc (NASDAQ:ARRY) stock a Buy, 5 rate the stock Outperform, 1 rate Hold, 0 rate Underperform and 0 recommend a Sell. Therefore 80% are positive.

Array BioPharma Inc. has a 52 week low of $6.73 and a 52 week high of $13.40.

Traders said the lower prices came after a report by the American Petroleum Institute (AI) late on Tuesday that showed a 9.2 million barrel rise in gasoline stocks in the week to December 1, and a boost of 4.3 million barrels in inventories of distillates, which include diesel and heating oil. Sage plc had 3 analyst reports since December 4, 2015 according to SRatingsIntel. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. Piper Jaffray maintained the stock with "Buy" rating in Wednesday, August 9 report. On Tuesday, January 10 the stock rating was maintained by BNP Paribas with "Neutral". On Sunday, September 10 the stock rating was maintained by Cowen & Co with "Buy". Piper Jaffray has "Buy" rating and $18.0 target. Cantor Fitzgerald maintained Array BioPharma Inc. As per Friday, February 19, the company rating was maintained by Credit Suisse. The firm earned "Buy" rating on Tuesday, October 31 by Stifel Nicolaus. Cantor Fitzgerald restated a "buy" rating and issued a $15.00 price target on shares of Array BioPharma in a research note on Tuesday, September 26th. On Thursday, July 13 the stock rating was maintained by Jefferies with "Buy".

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE